Roche View On Biogenerics: “They Will Come,” But Process Won’t Be Simple

Roche's ongoing supply agreement with Centocor for the thrombolytic Retavase illustrates the practical obstacles to commercialization of generic biologics, Roche Global Pharmaceuticals Head William Burns told a securities analysts briefing July 23 in Zurich